成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook--->CAS DataBase List--->1226549-49-0

1226549-49-0

1226549-49-0 Structure

1226549-49-0 Structure
IdentificationBack Directory
[Name]

DBPR112
[CAS]

1226549-49-0
[Synonyms]

DBPR112
(S,E)-4-(dimethylamino)-N-(3-(4-((2-hydroxy-1-phenylethyl)amino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide
2-Butenamide, 4-(dimethylamino)-N-[3-[4-[[(1S)-2-hydroxy-1-phenylethyl]amino]-6-phenylfuro[2,3-d]pyrimidin-5-yl]phenyl]-, (2E)-
[Molecular Formula]

C32H31N5O3
[MDL Number]

MFCD32263034
[MOL File]

1226549-49-0.mol
[Molecular Weight]

533.62
Chemical PropertiesBack Directory
[storage temp. ]

Store at -20°C
[solubility ]

DMSO : 250 mg/mL (468.50 mM; Need ultrasonic)
[form ]

Solid
[color ]

Off-white to light yellow
Spectrum DetailBack Directory
[Spectrum Detail]

DBPR112(1226549-49-0)1HNMR
Hazard InformationBack Directory
[Biological Activity]

DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy[1]. DBPR112 (compound 78; 0.32-1000 nM; 16 hours) induces reduction of phosphorylated EGFR in a dose-dependent manner[1]. DBPR112 shows the inhibitory activity against HCC827 (CC50=25 nM), H1975 (CC50=620 nM) and A431 Cell (CC50=1.02 μM) cell lines[1]. DBPR112 occupies the ATP-binding site and interacts with surrounding residues by covalent bonding, hydrogen bonds, and hydrophobic interactions, which give it a potent inhibitory activity against WT EGFR[1]. DBPR112 (orally; 20-50 mg/kg; 5 days/week for 2 consecutive weeks) significantly reduces tumor growth in HCC827 tumor model. DBPR112 (orally; 50 mg/kg; once a day for 15 days) has a significant antitumor effect (mean tumor growth inhibition of 34%) in H1975 tumor model[1]. DBPR112 (IV; 5 mg/kg) has a T1/2 of 2.3 hours, a CL of 55.6 mL/min?kg, and a Vss of 8.6 L/kg for rats[1].
[References]

[1]. Lin SY, et al. Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem. 2019 Nov 27;62(22):10108-10123.
1226549-49-0 suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000 , +1-00000000000
Website: https://www.targetmol.com/
Company Name: TargetMol Chemicals Inc.
Tel:
Website: www.targetmol.com/
Company Name: Aladdin Scientific
Tel: +1-+1(833)-552-7181
Website: www.aladdinsci.com/
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Website: www.bio-fount.com
Company Name: DC Chemicals  
Tel: 021-58447131 13564518121
Website: http://www.is0513.com/ShowSupplierProductsList927327/0.htm
Company Name: cjbscvictory  
Tel: 13348960310 13348960310
Website: http://www.weikeqi-biotech.com/
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Website: https://www.targetmol.cn/
Company Name: Shanghai Yifei Biotechnology Co. , Ltd.  
Tel: 021-65675885 18964387627
Website: http://www.efebio.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Website: www.ruidiresearch.com
Company Name: Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd.  
Tel: 025-66061636 18013972705
Website: www.aikonchem.com/
Tags:1226549-49-0 Related Product Information